A Study of Chemoembolization with or without Sorafenib (chemotherpay drug) with Unresectable Liver Cancer (Hepatocellular Carcinoma)

What we are studying

The purpose of this study is to see if localized chemotherapy to the liver (chemoembolization) combined with sorafenib will help patients live longer than treatment with chemoembolization alone.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnosed with Hepatocellular Carcinoma (liver cancer) recently and not a candidate for surgery
  • No previous treatment of Chemotherapy for this cancer
  • No history of stomach or intestinal bleeding problems
  • No evidence that this cancer has spread beyond your liver

What is involved

  • Monthly visits
  • Treatment with Sorafenib or placebo (sugar pill)
  • Blood tests
  • Chest x-rays
  • MRI scans
  • CT scans
  • Chemotherapy injected directly into your liver (chemoembolization)

Compensation

Sorafenib or placebo will be provided by the study. No other compensation will be provided.

Details

If contacting the study coordinator about this trial, please refer to study #CTSU E1208.

Contact Information

Study Coordinator
Joyce Fenstermaker
Email
jfenster@wakehealth.edu
Phone
336-713-3155

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.